Stock Market Reviews

APGE (Apogee Therapeutics, Inc.) News

Get the latest news, insights, and market updates on APGE (Apogee Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect?
  The consensus price target hints at a 72.5% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
  Oct 14, 2025 - $APGE
• Does Apogee Therapeutics' (APGE) $300 Million Raise Mark a Shift in Its R&D Ambition?
  Apogee Therapeutics, Inc. recently completed a follow-on equity offering, raising approximately US$300 million through the sale of 6,951,221 shares of common stock and pre-funded warrants to support its research programs. This move notably bolsters Apogee's cash reserves for advancing clinical and preclinical development in challenging inflammatory and immunology markets, such as atopic dermatitis and asthma. We'll now explore how this significant capital raise to support R&D initiatives...
  Oct 10, 2025 - $APGE
• Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
  SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 8,048,782 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,097,561 additional s
  Oct 10, 2025 - $APGE
• Apogee Therapeutics (APGE): Assessing Valuation Following $300 Million Equity Raise
  Apogee Therapeutics, Inc. (APGE) has just closed a $300 million follow-on equity offering by selling new shares and pre-funded warrants to investors. This fresh capital will support the company’s ongoing R&D and pipeline initiatives. See our latest analysis for Apogee Therapeutics. Apogee Therapeutics’ share price has surged 38% over the past month, with this momentum accelerating sharply following the $300 million equity raise. Investors appear to be betting on future growth after a muted...
  Oct 10, 2025 - $APGE
• Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
  SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 6,951,221 shares of its common stock at a public offering price per share of $41.00 and, in lieu of common stock to certain investors,
  Oct 9, 2025 - $APGE
• Why Apogee Therapeutics Stock Triumphed on Thursday
  The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.
  Oct 9, 2025 - $APGE
• Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
  Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.
  Oct 9, 2025 - $APGE
• Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
  SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stoc
  Oct 8, 2025 - $APGE
• RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating
  Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25, RBC Capital initiated coverage of Apogee Therapeutics Inc. (NASDAQ:APGE) with an Outperform rating and a $60 price target. The firm expressed optimistic sentiments regarding the company’s potential to deliver clinically differentiated biologics, telling […]
  Sep 30, 2025 - $APGE
• Apogee Therapeutics Shares Poised for Upside as Pipeline Targets Multiple Immunology Indications, RBC Says
  Apogee Therapeutics (APGE) shares have room to appreciate, especially with additional clinical data
  Sep 25, 2025 - $APGE